Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Synthetic Biosensors Market size was over USD 28.2 billion in 2024 and is poised to reach USD 68.6 billion by the end of 2037, registering at a CAGR of 7.7% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of synthetic biosensors is estimated at USD 30.3 billion.
Synthetic biosensors are emerging as game-changers, especially in the field of healthcare and research sciences with the provision of value for money. These are also considered state-of-the-art technologies to revolutionize disease detection and tracking and elevate the monitoring ability to improve health conditions. For instance, in November 2024, DexCom, Inc., and ŌURA initiated a strategic partnership to assist the global population by improving their metabolism through the integration of Dexcom glucose data. This device is stipulated to evaluate heart condition, stress levels, sleep routine, and activity data from Oura Ring, hence a positive impact driving the synthetic biosensors market.
Apart from the health sector, synthetic biosensors are also utilized for food quality control, military, environmental monitoring, industrial process control, and microbiology. As per the December 2022 NLM report, there are various types of nanomaterials present in biosensors including graphene-based, gold nanoparticles, carbon-based, fluorescent semiconductor nanocrystals, cell-based, and MOF and COF-based, positively impact the demand for synthetic biosensors market. In June 2024, Nix Biosensors inaugurated Nix Pro, a revolutionary group hydration monitoring device for labor groups and the military to enhance performance and reduce injuries, thereby an optimistic outlook for the market to grow.
Moreover, the efforts of healthcare organizations to integrate cost-effective, user-friendly, urbane, and accessible biosensor tests to end-users are boosting the market development. In this regard, the WHO suggested an effective payer's pricing to range between USD 1.0 to USD 10.0 to serve the purpose, as stated in the January 2024 NLM report. For instance, in 2020, a WHO-led international partnership commenced initiatives to establish the USD 5.0 cost-per-biosensor test for point-of-care applications in low- to middle-income regions. Besides, the cost of commercial tests usually ranges between USD 5 to USD 50, thus aiming to reduce biosensor pricing through engineered production of synthetic receptors.
Synthetic Biosensors Sector: Growth Drivers and Challenges
Growth Drivers
- Rise in demand for portable diagnostic tests: A case study conducted by Tata Elxsi in 2024 reported that the need for diagnostic tests has exceeded over 1 billion globally. Active and vibrant lifestyles and rising health awareness among consumers globally are increasing the demand for such tests, which in turn is driving the synthetic biosensors market. For example, portable automated rapid testing (PART) is a portable program to monitor auditory assessment and tends to produce suitable laboratory results, as stated in the October 2020 report of the Acoustical Society of America.
- Advancement in drug distribution: Technology and automation are driving the need for automation in drug delivery. In July 2023, AstraZeneca developed cell-targeted delivery of therapies with lipid nanoparticles with an 80% aim to reach internal cells and large molecules including nucleotide-based therapies. Moreover, a review conducted by the Computers in Biology and Medicine in August 2024, the implementation of tele-mechanics can ensure 50 new treatments in the upcoming 10 years and save up to USD 50 billion in pre-clinical alone, thus uplifting the market.
Challenges
- Lack of standard manufacturing procedure: Poor production process of synthetic biosensors leads to inefficient recording and transformation of biorecognition signals, insufficient increase in transducer performance, and miniaturization of the biosensing devices that use nano and micro-fabrication, as denoted by NLM in its February 2021 report. However, the adoption of sensing technology that ranges between 0 to 3 dimensions with suitable conductivities, color tunability, high surface-to-volume ratio, and shock-bearing abilities can overcome the challenges, thus constituting an optimistic outlook for the synthetic biosensors market.
- Limited shelf-life: The durability of a biosensor can be determined within four days and its continuous use stability in 24 hours. In addition, the durability of advanced biosensors is between six months to one year, and the life span ranges between one to three years, depending upon the usability, manufacturing method, and the type of measured gas. Besides, the confined temperature range also negatively impacts the longevity of these devices, thereby causing a major restraint in the evolution of the synthetic biosensors market globally.
Synthetic Biosensors Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.7% |
|
Base Year Market Size (2024) |
USD 28.2 billion |
|
Forecast Year Market Size (2037) |
USD 68.6 billion |
|
Regional Scope |
|
Synthetic Biosensors Segmentation
Design Type (Embedded Device, Sensor Patch)
Embedded device segment is anticipated to capture synthetic biosensors market share of over 64.5% by 2037, based on the design type. Factors including easy placement, real-time and continuous sensing facility, and complete absence of obstructions in regular functions are responsible for the necessity of embedded biosensors. As per a study conducted by MDPI in October 2021, the interferometric polymer-based electro-optical device is an integrated and embedded double-monolayer graphene capacitor for biosensing purposes. A finite element method measured the wavelength of the sensor which was 1.57 @ 800 nm and the PMMA cladding was 1.49 @ 800 nm, denoting a standard embedded biosensor.
Modality (Wearable, Non-wearable)
In synthetic biosensors market, wearable segment is set to dominate revenue share of over 60.1% by 2037. Wearable biosensors provide healthcare personnel with the possibility to evaluate important signs of health remotely for patients with chronic disorders. For instance, in October 2024, STMicroelectronics launched the latest ST1VAFE3BX chip for wearables such as smart glasses and watches, connected rings, and sports bands. The chip in combination with a high-accuracy biopotential input and the organization’s AI core ensures activity detection for rapid performance with reduced power consumption, thus driving the market development.
Our in-depth analysis of the global synthetic biosensors market includes the following segments:
|
Design Type |
|
|
Modality |
|
|
Technology |
|
|
Application |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportSynthetic Biosensors Industry - Regional Synopsis
North America Market Analysis
North America synthetic biosensors market is expected to hold revenue share of more than 46.9% by 2037. Factors such as the strong presence of organizations and extensive funding for research and development are driving the growth of the market in the region. For instance, in December 2024, Stemloop, Inc. received catalytic funding from the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office following its AI-based biotechnology to produce training information for machine learning (ML) models of next-generation biosensors. This funding also ensured a global position for the company with a track record of USD 2.7 million in non-dilutive funding and USD 1 million in pre-seed venture capital.
The U.S. synthetic biosensors market is gaining traction due to the increasing need for point-of-care (PoC) testing, technology advancements, rising chronic diseases, focus on tailored medicines and extension of applications beyond healthcare. In June 2024, the U.S. Food and Drug Administration (FDA) approved the market authorization of the Xpert HCV test and GeneXpert Xpress System, a hepatitis C virus (HCV) test, to ensure appropriate diagnosis with certified point-of-care settings for patients suffering from the virus. This denotes advancements in healthcare facilities in the country that are expanding the economy, ensuring public health and safety, thereby uplifting the market effectively.
The synthetic biosensors market in Canada is witnessing significant growth since there has been an escalation in the burden of the healthcare sector in the country. According to the December 2024 Canadian Medical Association report, over 6.5 million of the population are devoid of regular medical care, and to combat this, the association supports the implementation of medical records systems that are utilized by care providers to share essential data about patients. Moreover, the health sector accounts for 16.4% of the nation’s workforce and 82% constitute female workers within an age range of 25-54 years, as stated by the 2024 Government of Canada which boosts the market growth.
Employment Share by Subsector
|
Subsector |
Employment (%) |
|
Hospitals |
39.5% |
|
Ambulatory healthcare services |
22.1% |
|
Social assistance |
20.7% |
|
Nursing and residential care facilities |
17.7% |
Source: Government of Canada 2024
APAC Market Statistics
The synthetic biosensors market in APAC is the fastest-growing region and is poised to witness lucrative growth during the forecast timeline. The adoption of nanotechnology-based biosensors is amplifying the growth of the device in the region, and as per the 2024 Asian J Agric & Biol. report, nano biosensors not only detect glucose, but also monitor proteins, DNA, toxins, and cholesterol. Besides, according to the International Journal of Pharmaceutical Sciences in its September 2024 report, thalassemia is a growing hematologic disorder with a 10% to 15% presence in Southeast and Middle East Asian countries and the adoption of nano and novel molecular biosensors is a solution to overcome this, hence positively impact the market growth.
The synthetic biosensors market in India is expecting substantial growth due to an enhancement in demand for these devices that aid in healthcare services, and several global organizations are launching biosensors for this purpose. In January 2024, Trinity Biotech plc stated a non-binding Letter of Intent with Bayer for the introduction of a continuous glucose monitoring (CGM) biosensor device in the country as well as in China. More than 100 million people in India suffer from Type 1 and Type 2 diabetes and owing to the increase in self-care awareness, both organizations aimed to enhance the CGM technology to ensure affordable and innovative healthcare quality.
The synthetic biosensors market in China is gaining exposure owing to an upgradation in the research and development facilities. According to the 2024 Asian J Agric & Biol. report, the country’s overall R&D investment for 2022 boosted by 10.4% to nearly USD 38 trillion along with an increase in GDP by 2.55%. Besides, organizational collaboration is another factor in the growing demand for biosensors in the country. For instance, in November 2023, DuPont declared a deal between its Liveo Healthcare Solutions and STMicroelectronics to introduce a smart wearable device with remote biosignal-monitoring, hence an optimistic contribution towards patient outcomes with biosensors.
Companies Dominating the Synthetic Biosensors Landscape
- TIVIC Health
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- BASF SE
- Cala Health, Inc.
- Abbott
- Spark Biomedical, Inc.
- GENERAL ELECTRIC
- BIOTRONIK
- Soterix Medical Inc
- SetPoint Medical
- Bruker Corporation
- Biolinq
- Royal Philips
Companies dominating the synthetic biosensors market are gaining rapid exposure due to efficient acquisition, partnership, and funding to increase the demand for devices to precisely monitor health levels among patients. For instance, in April 2024, Royal Philips stated its strategic partnership to incorporate smartQare’s advanced solution with its own clinical patient monitoring platforms to ensure next-generation biosensors for nursing patients both within and outside of hospitals, thus a positive impact on the market development.
In the News
- In October 2024, Bruker Corporation declared the acquisition of Dynamic Biosensors GmbH to expand its biophysical portfolio for the evaluation of molecular kinetics and interactions, and provision of deeper insights into both inter-molecular and molecule-single cell interactions in drug discovery or basic research.
- In June 2024, Biolinq stated an investment of USD 58 million for a wearable patch-based biosensor to evaluate both activity and glycogen levels with the utilization of confined electrochemical sensors. The purpose of the investment was to ensure clinical trials and receive FDA approval for the device.
Author Credits: Radhika Pawar
- Report ID: 7173
- Published Date: Feb 18, 2025
- Report Format: PDF, PPT
